波士顿是中国科学技术大学海外校友最集中的三大城市之一。数以千计的中国科大校友曾经在波士顿学习，工作和生活。波士顿也因此成为勤奋的中国科大人书写传奇，挥洒才华的乐土。四十年来，中国科大校友活跃于波士顿的医药，金融，IT等高科技领域。中国科学技术大学波士顿校友会已经陆续推出校友行业沙龙聚会，旨在促进校友职业交流，搭建波士顿中国科大校友平台！2016年10月02日，波士顿科大校友会将举办第二届医药行业校友沙龙聚会。我们有幸邀请到波士顿医药界四位资深校友陈寅（808），张引（813）, 林华茂（888）和王晖（9208）作为演讲嘉宾，纵论中美医药行业发展的机遇和挑战，并分享作为科大校友在医药行业发展的心得体会。欢迎大家到来参加。
——中国科大波士顿校友会医药行业校友沙龙
生物制药工业以及生命健康行业在全球范围内蓬勃发展，并已成为美国新兴支柱产业之一，其产值于2010年达到约五千亿美元。在麻省理工学院（MIT)周围不到一平方公里的土地上，聚集着数百家以创新药物研发为目标的生物医药公司，以波士顿几十所研究性科研院校为依托，凭借着人才技术集约优势，波士顿一跃美国生物医药领域的“麦加”，引领生物医药行业的发展潮流。生物医药行业在中国也将有远大前景，据艾美仕（IMS）预测，2020年我国生物医药市场将成为仅次于美国市场的全球第二大生物医药市场。
面对机遇和挑战，演讲嘉宾将以生物医药为主线，进入其上下游，探讨金融投资和资本服务，专利申请，医疗保险状况和国际商务。为听众带来全新的视角和纬度。纵然您并非是业内人士，但如今身在波士顿且事关生命健康，何妨聆听讲座，激发新的灵感，并与校友在叙旧时情谊？
时间：2016年10月2日 14：00- 16:00
地点：MIT Tang Center (E51) Room-151
70 Memorial Dr, Cambridge, MA 02142
演讲嘉宾：
陈寅（808）：Director of Business Development at Accelagen, Founder/President/CEO at MTT Pharmaceuticals
张引（813）： Co-founder and chairman of the law firm of Milstein Zhang & Wu LLC
林华茂（888）：Takeda Pharmaceuticals
王晖（9208）：CFA， Managing and Founding Partner of HighLight Capital
备注：
1. 请注册确认参加活动：
2. 为保证会场秩序，请提前10分钟入场，望不要迟到。
3.我们欢迎非科大校友参加本次活动
4.现场联系人 霍宇达（0508）： 6176786876
附录：部分演讲嘉宾简介
陈寅 （808）
Dr. Yin Chen is a biotech entrepreneur with over 15 experiences in the industry. After serving as Chief Scientific Officer in a biotech company for 9 years, he co-foundered and became President/CEO of MTT Pharmaceuticals in 2008. Dr. Chen is currently consulting for several US and international pharmaceutical companies for product marketing, business development and fund raising.
Dr. Chen received his Bachelor of Science degree from University of Science & Technology China, Master of Science degree from Shanghai Institute of Biochemistry and Ph.D degree from University of Maine. He subsequently completed his postdoc training at Beth Israel Deaconess Medical Center/Harvard Medical School. In 2013, Dr. Chen earned his EMBA from Jack Welch Management Institute.
张引（813）
Dr. Philip Zhang is co-founder and chairman of the law firm of Milstein Zhang & Wu LLC. Dr. Zhang is a licensed lawyer and a registered patent attorney. He has practiced law in the U.S. for 17 years. Dr. Zhang has extensive experience representing pharmaceutical, biotechnology, clean technology, advanced materials, medical devices, and scientific instruments companies, including advising clients on IP strategies, product patent clearance, licensing and patent preparation and prosecution. Dr. Zhang also helps clients with IP issues in R&D collaborations, venture funding, mergers and acquisitions, and other corporate transactions. He is a frequent speaker and has published extensively on various legal, IP and technology issues including three articles in the journal Nature Biotechnology.
Dr. Zhang received his J.D. from Vanderbilt University Law School and his Ph.D. from Dartmouth College. He graduated with a B.Sci. from the University of Science & Technology of China.
王晖（9208）
Mr. Steven Wang is former senior partner and investment committee member of CDH. He has more than 10 years of experience in the medical industry and healthcare investment and focuses exclusively on healthcare services, medical device and pharmaceutical sectors. Prior to CDH, Mr. Wang served at Avenue Capital, Lehman Brothers (London) and Becton Dickinson Group. Over the last ten years, Mr. Wang was responsible for transactions totaling more than one billion dollars, including mergers & acquisitions, restructuring of publicly listed companies, growth and early stage investments.
Some of Mr. Wang’s representative deals include Kanghong Pharm (002773), KangNing Hospital (HK.02120), New Eyes (430140), Yuwell (002223), Syn The All Pharmaceutical(832159), Linwha(835637), TriPath Imaging (Nasdaq: TPTH), Poly, New Century Hospital, Angel’s Women and Children Hospital, New Century, Malo Clinic, Quyiyuan (quyiyuan.com), Dr. Cuiyutao etc.
1 Comments, RSS